 | | Vol. 17.22 – 8 June, 2022 |
| |
|
|
| Investigators discovered that TRIM66 and DAX1 functioned together as negative regulators of the 2-cell-like state in mESCs.
[Cell Stem Cell] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists proposed a strategy of modeling the post-attachment human embryo by assembling a pre-formed polarized epithelial epiblast and extraembryonic cells, allowing them to self-organize into a structure that mimicked the dish-attached human embryo.
[Cell Stem Cell] |
|
|
|
| The authors showed that naïve hESCs could transdifferentiate into trophoblast stem cells, but primed hESCs could not.
[Nature Communications] |
|
|
|
| Using a CRISPR-Cas9 knockout library screen in mESCs, researchers identified the E3 ubiquitin ligase Stub1 as a negative regulator of pluripotency.
[Cell Reports] |
|
|
|
| TET1 maintains hypomethylation at bivalent promoters through its catalytic activity in ESCs. Using a proteomics approach, scientists mapped the TET1 interactome in ESCs and identified PSPC1 as a TET1 partner.
[Cell Reports] |
|
|
|
| Mouse ESCs have revealed transcriptional and epigenetic control of early embryonic development. Researchers showed marked changes in morphology and actin architectures during differentiation that depended on Arp2/3 complex but not formin activity.
[Stem Cell Reports] |
|
|
|
| Scientists developed a xeno-free ON2/AscleStem PSC medium (ON2) and cultured 253G1 hiPSCs on different matrices, including iMatrix-511 and gelatin nanofiber in ON2.
[Stem Cell Research & Therapy] |
|
|
|
| Mouse embryonic fibroblasts were treated by methanol to generate chemical fixed feeder cells, and bovine ESCs F7 were cultured on this feeder layer.
[Scientific Reports] |
|
|
|
|
| The authors discuss recent advances in iPSC technology that have made it possible to generate patient-derived dopaminergic neuronal cell culture and organoid models of Parkinson’s disease.
[Trends in Neurosciences] |
|
|
|
| Investigators summarize the advantages, limitations, and future directions of cell replacement therapy, discuss the safety and ethical concerns of this novel therapeutic approach and the possibility of translation to clinical practice.
[Ageing Research Reviews] |
|
|
|
|
| Axol Bioscience Ltd. announced that its hiPSC-derived ventricular cardiomyocytes have undergone comprehensive in vitro pro-arrhythmia assay (CiPA) validation. Using this assay, the cells were shown to be suitable for measuring cardiotoxicity.
[Axol Bioscience Ltd.] |
|
|
|
| Altos Labs announced that it has signed a sponsored research agreement with the Center for iPS Cell Research and Application (CiRA) at Japan’s Kyoto University.
[Altos Labs (Cision US, Inc.)] |
|
|
|
|
| September 29 – 30, 2022
London, England, United Kingdom |
|
|
|
|
|
| | Francis Crick Institute – London, England, United Kingdom |
|
|
|
| | Cleveland Clinic – Cleveland, Ohio, United States |
|
|
|
| | University Medical Center Utrecht – Utrecht, Netherlands |
|
|
|
| | Stem Cell Network – Ottawa, Ontario, Canada |
|
|
|
| | Wellcome Sanger Institute – Cambridge, England, United Kingdom |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
